Moderna's Cancer Vaccine Euphoria Hits Profit-Taking Wall: $18 Billion Wipeout

Moderna saw its record-breaking surge following historic cancer vaccine trial results quickly erased by aggressive investor profit-taking. The company's market valuation plummeted by $18 billion in a single day, falling to $51.5 billion.

The Volatility Test of the mRNA Revolution

After a staggering 176% jump on Wednesday that more than doubled its value, Moderna faced a sharp correction on Thursday. Shares plunged more than 25%, retreating from above $174 to approximately $129.

■Market Cap Loss: $18 billion

■Current Valuation: $51.5 billion

■Peak Price: $174

■Current Level: $129

A 'Watershed Moment' in Melanoma Treatment

Despite the sell-off, Wall Street remains bullish on the clinical results of the personalized mRNA shot combined with Merck's Keytruda. The treatment is being hailed as a turning point for reducing melanoma recurrence and extending patient survival.

■Bank of America analyst Alec Stranahan quadrupled his price target from $40 to $170.

■The move is seen as a strategic diversification away from infectious diseases into oncology.

■However, uncertainty regarding how much better the combination is compared to Keytruda alone is fueling caution.

The Billionaire Wealth Swing

The extreme stock volatility led to dramatic shifts in the net worth of the company's leadership:

■CEO Stéphane Bancel: Fortune rose by $2.5 billion before falling by $1.3 billion, settling at $4.4 billion.

■Co-founder Thomas Langer: His ~3% stake pushed him back into billionaire status, though he faced a significant pullback from the peak.

■Co-founder Noubar Afeyan: Net worth dipped from $2.2 billion to $2.1 billion.

The Financial Divide

Moderna's technological breakthroughs contrast sharply with its fundamental financial health. The company reported a net loss of $782 million on revenue of $145 million in its latest quarter, proving that the market is pricing the company on future potential rather than current earnings.

From a macro strategy perspective, this looks less like a standard 'sell the news' event and more like the unwinding of an overextended gamma position. While volatility is inherent in biotech, an $18 billion wipeout suggests institutional investors are recalibrating their risk premiums. With a $782 million net loss still on the books, the valuation is entirely decoupled from current earnings and tethered to future promises. Expect short-term consolidation, but if the oncology pipeline delivers, this dip will be viewed as a mere breather in a long-term bull run.